Survival status of HIV/AIDS patients after antiretroviral treatment initiating at different times in Fengtai District of Beijing
LI Yanqi1, LIU Chao2, SHANG Cui1, SI Fenfen1, WANG Xinxin1
1. Fengtai District Center for Disease Control and Prevention, Beijing 100071, China; 2. Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
Abstract：Objective To analyze the survival status and influencing factors of human immunodeficiency virus (HIV)infected/acquired immunodeficiency syndrome (AIDS) patients after antiretroviral therapy initiating at different times in Fengtai District of Beijing. Methods We collected the data about HIV/AIDS patients with antiretroviral therapy in Fengtai District during 2005-2021 from the National Integrated AIDS Prevention and Control Information System. According to the adjustment time of antiretroviral treatment policy, the subjects were divided into the treatment year group of 2005-2007, the treatment year group of 2008-2011, the treatment year group of 2012-2015, and the treatment year group of 2016-2021. A retrospective study was carried out using survival analysis method. Results A total of 3,618 cases were enrolled into this study, including 29 (0.80%) cases in the treatment year group of 2005-2007, 244 (6.74%) cases in the treatment year group of 2008-2011, 1,388 (38.36%) cases in the treatment year group of 2012-2015, and 1,957 (54.09%) cases in the treatment year group of 2016-2021. The one-year cumulative survival rates of the 4 treatment year groups were 92.98%, 98.35%, 98.75% and 98.86% respectively, and the five-year cumulative survival rates were 89.41%, 95.33%, 97.34% and 98.25% respectively. The differences in the survival times of patients in different treatment year groups were statistically significant (χ2=8.386, P=0.039). Multivariate Cox proportion hazard models revealed that the risk of death was higher in patients initiating antiretroviral therapy at the age of ≥50 years than in those initiating antiretroviral therapy at the age of 15-29 years (HR=3.95, 95%CI:1.82-8.56), and the patients initiating antiretroviral therapy at CD4 lymphocyte count <200 cells/μl at the baseline had a higher risk of death than those initiating antiretroviral therapy at CD4 lymphocyte count ≥500 cells/μl at the baseline (HR=12.30, 95%CI:2.97-50.88). Conclusion With the continuous optimization of antiretroviral therapystrategies and measures against HIV/AIDS, the risk of death after antiretroviral therapy initiating at different times in Fengtai District has been gradually reduced. More attention and support should be paid to cases within one year of antiretroviral therapy and aged ≥ 50 years.In future,it is necessary to continuously promote early detection and treatmentand constantly improve antiretroviral therapy so as to ameliorate the therapeutic effect.
李彦奇, 刘超, 尚翠, 司芬芬, 王欣心. 北京市丰台区不同时期开始抗病毒治疗HIV/AIDS生存状况分析[J]. 实用预防医学, 2023, 30(7): 775-780.
LI Yanqi, LIU Chao, SHANG Cui, SI Fenfen, WANG Xinxin. Survival status of HIV/AIDS patients after antiretroviral treatment initiating at different times in Fengtai District of Beijing. , 2023, 30(7): 775-780.
[1] 李兰娟,任红. 传染病学[M].第9版.北京:人民卫生出版社,2018:122. [2] 张福杰,赵燕,马烨,等.中国免费艾滋病抗病毒治疗进展与成就[J].中国艾滋病性病,2022,28(1):6-9. [3] 焦艳梅,杨鸿鸽,王福生.艾滋病功能性治愈研究的进展及挑战[J].中国艾滋病性病,2017,23(1):91-94. [4] 陈欢欢,刘鹏涛,阮玉华.我国免费艾滋病抗病毒治疗策略与“治疗即预防”进展情况[J].中国热带医学,2019,19(12):1194-1196. [5] 张福杰. 国家免费艾滋病抗病毒治疗手册[M].第2版.北京:人民卫生出版社,2008:24-28. [6] 张福杰. 国家免费艾滋病抗病毒治疗手册[M].第3版.北京:人民卫生出版社,2012:15-18. [7] 张福杰. 国家免费艾滋病抗病毒治疗手册[M].第4版.北京:人民卫生出版社,2016:15-16. [8] 韩孟杰,金聪,李敬云,等.扩大艾滋病检测促进早检测专家共识[J].中国艾滋病性病,2021,27(11):1202-1206. [9] 李翔,买吾拉尼·买买提依明,崔莹莹.2002—2020年乌鲁木齐市接受艾滋病抗病毒治疗患者生存及影响因素分析[J].职业与健康,2022,38(12):1658-1662,1665. [10] 傅洁,岳清,庄鸣华,等.上海市2005—2017年艾滋病抗病毒治疗患者生存情况分析[J].实用预防医学,2020,27(11):1345-1348. [11] Arber DL,Andrade BB,Sereti I,et al. Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none[J].Nat Rev Microbiol, 2012,10(2):150-156. [12] 金屡华,唐慧玲,张子根.金华市AIDS病人抗病毒治疗病毒学失败情况分析[J].中国艾滋病性病,2017,23(12):1145-1148. [13] 陈婧,徐敏,赵啸,等.北京市 2005—2015年艾滋病抗病毒治疗患者生存及其影响因素[J].中华疾病控制杂志,2018,22(12):1225-1228. [14] Zhao Y,Wu ZY,McGoogan JM,et al.Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China: a nationwide,retrospective cohort study[J].Clin Infect Dis,2018,66(5):727-734. [15] Wang LY,Ge L,Wang L,et al.Causes of death among AIDS patients after introduction of free combination antiretroviral therapy(cART) in three Chinese provinces,2010-2011[J].PLoS One, 2015,10(10):e0139998. [16] 王伟,张亚丽,马琳,等.2011—2019年河北省≥50岁HIV感染者/AIDS 患者接受抗病毒治疗后生存时间及影响因素分析[J].职业与健康,2021,37(23):3223-3226. [17] 江光煚,吴国辉,裴迎新,等.中国老年人群HIV感染现况及行为学特征研究进展[J].实用预防医学,2019,26(4):510-513. [18] Lodi S,Phiuips A,Touloumi G,et al.Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds ＜200,＜350,and ＜500 cells/mm3,assessment of need following changes in treatment guidelines[J].Clin lnfect Dis,201l,53(8):817-825. [19] Smith CJ,Ryom L,Weber R,et al.Trends in underlying causes of death in people with HIV from 1999 to 2011(D:A:D): a multicohort collaboration[J].Lancet,2014,384(9939):241-248. [20] Chen L,Pan X,Ma Q,et al.HIV cause-specific deaths,mortality,risk factors,and the combined influence of HAART and late diagnosis in Zhejiang,China,2006-2013[J].Sci Rep,2017,7:42366. [21] 邱月锋,吴守丽,夏品苍,等.福建省2004—2020年成人艾滋病抗病毒治疗患者生存情况及影响因素分析[J].中国艾滋病性病,2022,28(1):92-96. [22] 蔡畅,汤后林,李东民,等.我国艾滋病患者的死亡趋势及其相关危险因素分析[J].中华流行病学杂志,2021,42(1):121-125.
2023, Vol. 30 
